Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain

• Susanne Hartz,
• Christophe Sapin,
• Bernd Schweikert,
• Chiara Malmberg,
• Mercedes Núñez,
• Tatiana Dilla

Affiliations

Susanne Hartz

Global Patient Outcomes and Real World Evidence International, Eli Lilly and Company, Windlesham, UK

Christophe Sapin

6 Eli Lilly and Company, Indianapolis, Indiana, USA

Bernd Schweikert

Real World Evidence Strategy and Analytics, Commercialisation and Outcomes, ICON, Munich, Germany

Chiara Malmberg

Access, Commercialisation and Communications, ICON, Munich, Germany

Mercedes Núñez

Health Outcomes and Real World Evidence, Eli Lilly and Company, Madrid, Spain

Tatiana Dilla

Global Patient Outcomes and Real World Evidence International, Eli Lilly and Company, Madrid, Spain